Novartis wins Gilenya reprieve as judge blocks generics, for now
The judge said letting generics makers sell their versions before the patent dispute was decided would damage the Swiss drugmaker more than those wanting a piece of Gilenya's market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 24, 2019 Category: Pharmaceuticals Source Type: news
FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs
[07-04-2015] The U.S. Food and Drug Administration is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis (MS). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Diving into the details: A lipid-binding pocket is a target for new cancer therapies
(Medical University of South Carolina) Cell growth is tightly controlled; however, cancer cells overcome the normal growth controls and proliferate uncontrollably. Researchers at the Medical University of South Carolina examined the molecular details underlying the interaction of ceramide, a lipid that plays a critical role in several signaling pathways, with a protein complex involved in modulating cell growth. They showed that ceramide and a similar compound, fingolimod, disrupt the interaction of SET with PP2A to repress cell growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2019 Category: Cancer & Oncology Source Type: news
Two Updates in Multiple Sclerosis Two Updates in Multiple Sclerosis
Dr Stephen Krieger on when anti-MOG antibody testing is warranted, and how to properly manage the risk for post-fingolimod rebound.Medscape Neurology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 26, 2019 Category: Radiology Tags: Neurology & Neurosurgery Commentary Source Type: news
Risk for Conversion of MS Varies With Different Therapies
WEDNESDAY, Jan. 16, 2019 -- For relapsing-remitting multiple sclerosis (MS), the risk for conversion to secondary progressive MS is lower with initial treatment with fingolimod, alemtuzumab, or natalizumab versus glatiramer acetate or interferon... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 16, 2019 Category: Pharmaceuticals Source Type: news
IDIBELL researchers identify a new leukodystrophy in children and its potential cure
(IDIBELL-Bellvitge Biomedical Research Institute) The Neurometabolic Diseases research team at IDIBELL and CIBERER, led by Aurora Pujol, has uncovered a novel disease of children affecting the brain white matter -- the myelin sheath --, leading to severe incapacity and death in some cases. These defects were corrected by a treatment with fingolimod, a drug in use for multiple sclerosis which interferes with this pathway. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 10, 2019 Category: International Medicine & Public Health Source Type: news
FDA: Stopping Fingolimod May Exacerbate MS
(MedPage Today) -- Rare effects including severely increased disability, multiple new lesions (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 21, 2018 Category: American Health Source Type: news
FDA Warns of MS Worsening After Stopping Fingolimod (Gilenya) FDA Warns of MS Worsening After Stopping Fingolimod (Gilenya)
The agency adds a new warning to the fingolimod label and patient medication guide about this risk, which can lead to permanent disability.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 21, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA warns about severe worsening of multiple sclerosis after stopping the medicine Gilenya (fingolimod)
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 20, 2018 Category: Drugs & Pharmacology Source Type: news
Switching to Alemtuzumab in MS, Keep Washout to a Minimum Switching to Alemtuzumab in MS, Keep Washout to a Minimum
Two new studies of patients switching from natalizumab or fingolimod to alemtuzumab suggest that shorter washout periods are better to reduce disease reactivation.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 24, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Natalizumab or Fingolimod After First-Line Drugs in MS? Natalizumab or Fingolimod After First-Line Drugs in MS?
A new propensity score analysis suggests natalizumab may have the edge over fingolimod for patients who experience relapse on first-line drugs, especially patients with more active disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
PARADIGMS: Fingolimod Effective, Well Tolerated in Children PARADIGMS: Fingolimod Effective, Well Tolerated in Children
Results show an 82% reduced annualized relapse rate among pediatric patients with multiple sclerosis taking fingolimod compared with those taking interferon-beta1a.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
WEDNESDAY, Sept. 12, 2018 -- Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events than interferon beta-1a, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 12, 2018 Category: Pharmaceuticals Source Type: news
New Drug Fingolimod (Gilenya) Could Help Kids With MS
WEDNESDAY, Sept. 12, 2018 -- Researchers say the first drug for children with multiple sclerosis vastly outperformed another common MS medication in a new clinical trial.
Fingolimod (Gilenya) reduced relapse rates by 82 percent in patients aged 10... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 12, 2018 Category: General Medicine Source Type: news
Natalizumab cost effective versus fingolimod for RRMS
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news
